Authors: Christina Claus, Claudia Ferrara, Wei Xu, Johannes Sam, Sabine Lang, Franziska Uhlenbrock, Rosmarie Albrecht, Sylvia Herter, Ramona Schlenker, Tamara Hüsser, Sarah Diggelmann, John Challier, Ekkehard Mössner, Ralf J. Hosse, Thomas Hofer, Peter Brünker, Catherine Joseph, Jörg Benz, Philippe Ringler, Henning Stahlberg, Matthias Lauer, Mario Perro, Stanford Chen, Christine Küttel, Preethi L. Bhavani Mohan, Valeria Nicolini, Martina Carola Birk, Amandine Ongaro, Christophe Prince, Reto Gianotti, Gregory Dugan, Christopher T. Whitlow, Kiran Kumar Solingapuram Sai, David L. Caudell, Armando G. Burgos-Rodriguez, J. Mark Cline, Michael Hettich, Maurizio Ceppi, Anna Maria Giusti, Flavio Crameri, Wouter Driessen, Peter N. Morcos, Anne Freimoser-Grundschober, Victor Levitsky, Maria Amann, Sandra Grau-Richards, Thomas von Hirschheydt, Stella Tournaviti, Michael Mølhøj, Tanja Fauti, Viola Heinzelmann-Schwarz, Volker Teichgräber, Sara Colombetti, Marina Bacac, Alfred Zippelius, Christian Klein, Pablo Umaña
Published: 2019-06-12
DOI: 10.1126/scitranslmed.aav5989
Source: Full article
Tumor-targeted 4-1BB agonists provide costimulation as combination partners for cancer immunotherapies in solid and hematological tumors.